AKT activation is associated with many malignancies, where AKT acts, in part, by inhibiting FOXO tumor suppressors. We show a converse role for AKT/ FOXOs in acute myeloid leukemia (AML). Rather than decreased FOXO activity, we observed that FOXOs are active in $40% of AML patient samples regardless of genetic subtype. We also observe this activity in human MLL-AF9 leukemia allele-induced AML in mice, where either activation of Akt or compound deletion of FoxO1/3/4 reduced leukemic cell growth, with the latter markedly diminishing leukemia-initiating cell (LIC) function in vivo and improving animal survival. FOXO inhibition resulted in myeloid maturation and subsequent AML cell death. FOXO activation inversely correlated with JNK/c-JUN signaling, and leukemic cells resistant to FOXO inhibition responded to JNK inhibition. These data reveal a molecular role for AKT/FOXO and JNK/c-JUN in maintaining a differentiation blockade that can be targeted to inhibit leukemias with a range of genetic lesions.
INTRODUCTION
The serine/threonine kinase AKT is a highly conserved central regulator of growth-promoting signals in multiple cell types. Deregulation of AKT has been associated with multiple human diseases including a wide variety of cancers (Altomare and Testa, 2005; Nicholson and Anderson, 2002) . AKT functions by phosphorylating and inactivating substrates that antagonize cell growth and survival, including PRAS40, GSK-3b, TSC2, BAD, and FOXOs (Brunet et al., 1999; Cross et al., 1995; Datta et al., 1997; del Peso et al., 1997; Inoki et al., 2002; Kops et al., 1999; Sancak et al., 2007) . The kinase activity and substrate selectivity of AKT are principally controlled by phosphorylation of threonine 308 (pAKT Thr308 ) and serine 473 (pAKT Ser473 ) (Alessi et al., 1996) . pAKT Ser473 is dispensable for AKT-mediated phosphorylation of TSC2 and GSK-3b, whereas pAKT Ser473 is required for phosphorylation and inactivation of the FOXOs (Guertin et al., 2006) .
Direct mutations in components of the PI3K signaling pathway are rarely observed in human AML; however, elevated AKT phosphorylation has been observed in $50% (Park et al., 2010) . pAKT Thr308 was shown to confer a poor prognosis in AML (Gallay et al., 2009) , whereas pAKT Ser473 correlates with a favorable response to chemotherapy (Tamburini et al., 2007) . In mouse models, constitutive activation of Akt or deletion of Pten, which suppresses Akt signaling, leads to myeloid or lymphoid neoplasia (Kharas et al., 2010b; Yilmaz et al., 2006) . Collectively, these observations have supported the general concept that activated AKT signaling is associated with hematopoietic malignancies.
The FOXO family of transcription factors comprises four highly related members-FOXO1, FOXO3, FOXO4, and FOXO6-that are direct downstream targets of AKT (Arden, 2006; Brunet et al., 1999; Kops et al., 1999; Fu and Tindall, 2008) . In the absence of active AKT, FOXOs localize to the nucleus where they regulate the transcription of genes involved in cell-cycle arrest, apoptosis, and reactive oxygen species (ROS) detoxification. Paradoxically, although FOXOs are primarily known as tumor suppressors, high FOXO3 expression is associated with adverse prognosis in AMLs exhibiting normal cytogenetics (Santamaría et al., 2009 ). Furthermore, genetic ablation of FoxO3 reduced disease burden in a murine model of chronic myeloid leukemia (CML) (Naka et al., 2010) .
AMLs are genetically heterogeneous malignant neoplasms that have a low survival rate (Frö hling et al., 2005) . AML prognosis is dependent on the cytogenetic and molecular profiles of AML cells (Armstrong et al., 2003; Dash and Gilliland, 2001; Dö hner et al., 2010) . The genetic and molecular diversity observed in AML has made the development of universal or broad AML-targeted therapies very difficult. Thus, investigation of the molecular signatures that separate AMLs into larger, more discrete groups is needed to develop more general and effective therapies.
We used human samples to assess the potential for AKT/ FOXO signaling to divide AML into broad groups, and we used both an established murine model and human AML cells to define whether targeting AKT/FOXO could affect disease. We unexpectedly observed that low levels of AKT activity associated with elevated levels of FOXOs are required to maintain the function and immature state of leukemia-initiating cells (LICs). Furthermore, depletion of FOXO3 promoted differentiation and apoptosis of human myeloid leukemia cells. These data reveal an unrecognized role of the AKT/FOXO signaling pathway in the regulation and maintenance of AML that runs counter to the established roles of AKT/FOXO signaling in human cancer. Finally, we also observed that inhibition of FOXO, either directly or via AKT activation, stimulates the JNK/c-JUN pathway, which suppresses AML cell apoptosis. These findings provide unique molecular insights into how growth-control pathway perturbation can participate in malignancy and identify specific molecular targets for differentiation-inducing approaches to a large proportion of myeloid leukemias.
RESULTS

AKT Activity Is Diminished in MLL-AF9 CD34 + Myeloid
Progenitors Because specific modifications of AKT confer distinct clinical outcomes of human AML (Gallay et al., 2009; Park et al., 2010; Tamburini et al., 2007) , we examined Akt status in a murine model of MLL-AF9-induced myeloid leukemia that closely phenocopies human AML (Krivtsov et al., 2006) . In this model, the L-GMP (leukemia-granulocyte macrophage progenitor) cell population, which shares the same immunophenotype of GMPs (lineage low , cKit high , Sca-1
, is enriched for LIC activity. Akt phosphorylation was assessed by flow cytometry in cells from healthy and MLL-AF9 leukemic mice. Normal myeloid progenitors displayed a robust increase in both pAkt Ser473 and pAkt Thr308 ( Figure 1A and Figure S1A available online); however, leukemic progenitors (enriched for L-GMPs) exhibited markedly reduced pAkt Ser473 and pAkt Thr308 in response to stimulation, indicating attenuated Akt activation ( Figure 1A and Figure S1A ). Cells were further evaluated for serine 235/236 phosphorylation of ribosomal S6 (pS6 Ser235/236 ), a downstream effector of AKT signaling (Burgering and Coffer, 1995) . Normal CD34 + cells showed strong induction of pS6 Ser235/236 ( Figure S1B ), whereas CD34 + leukemic progenitors had a blunted pS6 Ser235/236 response, further demonstrating that Akt activity is diminished in MLL-AF9 LIC-enriched populations ( Figure S1B ).
Constitutive Activation of Akt Promotes Myeloid Differentiation and Apoptosis of Murine AML Cells
The diminished Akt activity in MLL-AF9-driven LICs and BCR-ABL-positive LICs (Naka et al., 2010) prompted us to determine the biological consequences of enforcing Akt activity in MLL-AF9-positive AML cells. To that end, bone marrow (BM) cells from MLL-AF9 leukemic mice were adapted to liquid culture and infected with recombinant retroviruses expressing a constitutively active form of Akt (myr-Akt). Cells expressing myr-Akt had markedly impaired proliferation compared to control-infected cells ( Figure 1B ), consistent with previous reports (Wang et al., 2008) . Ablation of Pten (an inhibitor of Akt signaling) in the murine hematopoietic system results in the rapid onset of myeloid and/or lymphoid neoplasia (Lee et al., 2010; Yilmaz et al., 2006) . Within this model, leukemogenesis is largely dependent on mammalian target of rapamycin (mTor) signaling, as rapamycin markedly delays disease onset (Yilmaz et al., 2006) . Enforced expression of myr-Akt strongly increased the phosphorylation of mTor substrates ( Figure S1D ). However, treatment of myr-Akt-expressing AML cells with effective concentrations of rapamycin did not completely rescue the cell growth defect (Figure 1B and Figure S1C ). Although these results do not exclude a role for mTor signaling, they do suggest that additional mechanisms might contribute to the cell growth defect associated with myr-Akt expression in murine AML cells. Expression of myr-Akt in normal bone marrow reduces the self-renewal properties of normal hematopoietic stem and progenitor cells (HSPCs) and promotes myeloid maturation (Kharas et al., 2010b) . Therefore, we examined whether myrAkt expression was inhibiting AML cell growth by promoting myeloid maturation. myr-Akt cells displayed increased forward and side scatter by cytometry, consistent with mature myeloid cells ( Figure S1E ). Further, mature myeloid cell markers (CD11b) were higher on myr-Akt cells ( Figure 1C) , and myr-Akt cells exhibited morphological changes of myeloid maturation including reduced nucleoli, increased cytoplasmic volume, granule formation, and condensed chromatin ( Figure 1D ). Finally, myr-Akt cells acquired the ability to engulf fluorescent-labeled bacterial peptides, confirming the myr-Akt-directed maturation of leukemic blasts into functional myeloid cells with the capacity for phagocytosis (Figures 1E and 1F) .
Upon completion of myelopoiesis, mature myelocytes have a limited life span in the peripheral blood. Therefore, we evaluated whether myr-Akt-induced maturation of myeloid cells is accompanied by increased cell death. Apoptosis was increased in myr-Akt myeloid cells ( Figure 1G ). Maturation-related death mediated by myr-Akt occurred in the presence of rapamycin, suggesting that Akt utilizes pathways other than mTor activation for myeloid maturation ( Figures 1C-1F ). Together, these results suggest that LICs within this model maintain low levels of Akt activity to preserve an immature cell state by preventing differentiation and death.
FoxOs Are Active in Murine MLL-AF9 L-GMPs FoxOs play central roles in regulating normal hematopoiesis and are integral mediators of Akt's actions in cellular growth and survival (Fu and Tindall, 2008; Miyamoto et al., 2007; Tothova et al., 2007; Yalcin et al., 2008) . We evaluated FoxO activity in L-GMPs by assessment of several well-established FoxO target genes. Cdkn1b (p27), Cited2, Ccrn4l, Meis1, Tmem71, and Ccng2 are all activated by FoxOs and were found to be upregulated in L-GMPs compared to GMPs (Figure 2A) . Ccnd1, Ccnd2, Atm, and Sox4, which are repressed by FoxOs, were documented to be downregulated in L-GMPs (Figure 2A ).
Because AKT-mediated phosphorylation of FOXOs leads to nuclear exclusion and subsequent inactivation (Brunet et al., 1999) , the nuclear localization of FoxO3 (the dominant FoxO family member active in the murine hematopoietic system; Miyamoto et al., 2007; Yalcin et al., 2008) was evaluated in normal GMPs and L-GMPs by immunofluorescence. FoxO3 was predominantly cytoplasmic in GMPs, whereas L-GMPs displayed nuclear localization of FoxO3 (Figures 2B) . Collectively, these data suggest that FoxOs are active in L-GMPs but do not exclude that they are also active in other AML cellular subsets. 
Deletion of FoxOs Promotes Myeloid
Depletion of FOXO3 Promotes Myeloid Maturation and Apoptosis of Human AML Cell Lines
To determine whether FOXO3 is also active in human AML cell lines carrying MLL-AF9 translocations, the cytoplasmic and nuclear fractions of THP-1 and Mono-mac-6 (MM6) cells were evaluated for FOXO3 expression. Similar to our murine model, FOXO3 was nuclear in these human AML cell lines with approximately equal distribution between the two cellular compartments. Furthermore, SKM-1 cells as well as a human acute promyelocytic leukemia (APL) cell line (NB4), neither of which bear MLL translocations, displayed 75% and 86% nuclear FOXO3, respectively, suggesting that FOXO3 may serve comparable biological roles in other forms of AML ( Figure 3A ). To determine human AML dependence on FOXOs, we used FOXO3 shRNA in cell lines with MLL-AF9 translocations (MOLM-14, THP-1, MM6, and NOMO-1), APL cell lines (HL-60 and NB4), and AML cell lines that do not carry MLL translocations (SKM-1 and U-937) ( Figure 3B and Figure S3A ). All eight cell lines expressing FOXO3 shRNA exhibited lower growth rates compared to control shRNA-expressing cells (Figure 3C and Figure S3B) . Depletion of FOXO3 resulted in increased CD11b expression ( Figure 3D and Figure S3C ) and morphological changes consistent with myeloid maturation ( Figure 3F and 
FOXO3 Is Activated in Primary AMLs Derived from Patients
To validate our findings in AML cell lines, the cellular distribution of FOXO3 was examined in primary BM cells derived from nine different AML patients. Biochemical fractionation displayed a wide variation between samples in the nuclear-to-cytoplasmic ratio of FOXO3 (3%-70% nuclear FOXO3) (Figures 4A and 4B; Figures S4A and S4B) . Five of the nine samples contained CD34 + blasts. Fluorescence-activated cell sorting (FACS) isolation of the CD34 + , lineage low population revealed enrichment for nuclear FOXO3 in comparison with fractionation of the total BM or CD34
À , lineage high cells ( Figure 4A and Figure S4A ). Within these five samples, the overall level of nuclear FOXO3 varied between 10%-70%. Depletion of FOXO3 reduced colony formation in methylcellulose and promoted myeloid maturation (by surface marker expression and morphology) in two samples ( Figures 4C-4E ).
To determine the global status of FOXO activity in AML, gene expression array data from murine hematopoietic stem cells (HSCs) with and without FoxO1/3/4 were utilized to generate a hematopoietic-specific gene signature of FOXO activity ( Figure 4F ; Table S1 ). Using this FoxO target gene set, unsupervised hierarchical clustering analysis of 436 primary AML samples was performed (Bullinger et al., 2004 ; Table S1 ).
(G) Hierarchical cluster analysis based on the overlap of the murine FOXO gene signature stratified over the gene expression array data of 436 individual primary AML samples. See also Figure S4 and Table S1 . Kharas et al., 2010a) . The differential expression of FOXO target genes stratified AML into two distinct clusters, strongly suggesting that these clusters reflect two distinct patterns of FOXO activity; cluster 1 AMLs display lower FOXO activity relative to AMLs within cluster 2 ( Figure 4G ). Consistent with this notion, FOXO1 and FOXO3 expression in cluster 2 (higher FOXO activity) is significantly elevated compared to cluster 1 (lower FOXO activity) (p < 0.0001; Figure 7C ). Each cluster was significantly represented in nine AML subgroups separated on the basis of defined chromosomal aberrations, indicating that FOXO activation is not restricted to a particular subtype of AML (p < 0.0001; Figure S4C ). However, AMLs bearing FLT3-ITD mutations (associated with poor prognosis) were underrepresented in the cluster 2 (higher FOXO activity) gene signature (p < 0.0001; Figure S4D ). Combined, these analyses extend the importance of FOXOs beyond MLL-AF9 + AMLs and suggest that FOXOs may impact a broad spectrum of myeloid leukemias of various genotypes. Figure 5A ). At the first presentation of AML, all mice from each group were euthanized and assessed for leukemic burden as defined by spleen weight and peripheral white blood cell (WBC) counts. Saline-and pI-pC-treated Cre À and saline-treated Cre + recipients all developed splenomegaly and leukocytosis ( Figures  5B-5D ; Figure S5A ). In contrast, pI-pC-treated Cre + transplanted mice retained normal spleen weights and WBC counts (Figures 5B-5D ; Figure S5A ).
MLL-AF9 Leukemic
To distinguish whether disrupting FoxO1/3/4 expression eliminated MLL-AF9 leukemia or merely delayed the onset, we evaluated the survival rates of Cre À and Cre + recipient mice that were given saline or pI-pC. Blood from recipient mice was analyzed every 4-14 days. Consistent with the prior findings, pI-pCtreated Cre + mice had lower WBC counts than saline-treated controls ( Figure 5D ). Regardless of pI-pC treatment, recipient mice transplanted with Cre À leukemic cells or those transplanted with saline-treated Cre + cells had similar latencies for AML ( Figures 5E and 5F ). In contrast, mice transplanted with pI-pCtreated Cre + leukemic cells (FoxO1/3/4 deleted) displayed a significantly longer latency. Interestingly, 20% of mice (n = 10) were disease free up to 5 months post-excision. However, despite efficient excision of FoxO1/3/4 ( Figures S5C-S5F ), the majority of mice eventually succumbed to leukemia (Figure 5F ), the basis for which we subsequently discovered as noted below. Figure S5G ). To test whether loss of FoxO1/3/4 also diminished LIC function, we performed a limit dilution assay. Leukemic BM cells from Cre + mice 7 days following pI-pC or saline treatment were transplanted into recipients at cell doses of 3 3 10 2 , 3 10 3 , 3 10 4 , 3 10 5 /animal. On day 130 post-transplantation, 17%, 50%, 100%, 100%, respectively (corresponding to the cell doses above), of saline-treated Cre + (+/+) mice succumbed to AML (LIC frequency = 1:5,314; Figure 5H ). In contrast, 0%, 0%, 25%, 100%, respectively, of mice transplanted with pI-pC- Figure 5F ( Figure S5B ). Taken together, these data demonstrate that FoxO1/3/4 expression modulates LIC activity in vivo.
Constitutive Activation of Akt Does Not Alter Disease Latency In Vivo
We examined the effects of expressing myr-Akt in MLL-AF9-induced leukemia cells in vivo. BM cells derived from mice transformed with MLL-AF9 were infected with either control or myrAkt recombinant retroviruses that also express GFP. Following infection, GFP + cells from each condition were isolated by FACS and separately injected into syngeneic recipients. Mice from all conditions succumbed to AML, and we did not observe any significant difference in latency between control and myrAkt-expressing AMLs ( Figure S5H ). The lack of impact on latency was unexpected and caused us to examine whether a mechanism of resistance to Akt activation had emerged. , 1994) . Depletion of FOXO3 resulted in substantial increases in pJNK Thr183/Tyr185 , pc-JUN Ser63 , and total c-JUN ( Figure 6A and Figure S6B ). Enforced expression of myr-Akt in murine MLL-AF9-expressing AML cells led to increased phosphorylation of FoxO3 Ser256 (pFoxO3 Ser256 ) as well as increases in pJnk Thr183/Tyr185 , pc-Jun Ser63 , and total c-Jun ( Figure 6D ). (H and I) Leukemic BM cells isolated from Cre + mice administered saline (H) or pI-pC (I) 7 days earlier were transplanted into tertiary recipients at various cell numbers: 300 (n = 6), 3,000 (n = 6), 30,000 (n = 4), and 300,000 (n = 4). Kaplan-Meier analysis of animals that developed leukemia is shown. LIC frequencies were calculated using poisson statistics (H: LICfreq +/+ = 1:5,314 and I: LICfreq D/D = 1: 86,044).
Inhibition of FOXO3 Results in
See also Figure S5 .
Pharmacological Inhibition of JNK Cooperates with FOXO Inhibition to Induce AML Cell Death
We then tested whether JNK/c-JUN signaling has a functional impact on cellular events induced by AKT and FOXO signaling. We combined a pan-JNK inhibitor (SP600125, Calbiochem) with either FOXO3 depletion or myr-Akt expression and evaluated the growth, differentiation, and survival of AML cells. Treatment of control-infected MOLM-14-, SKM-1-, or MLL-AF9-expressing murine leukemia cells with SP600125 caused a modest but significant decrease in cell growth and a mild increase in mature myeloid surface marker expression and apoptosis ( Figures 6B, 6C , 6E, and 6F; Figures S6C-S6E ). As seen previously, depletion of FOXO3 or myr-Akt resulted in significant decreases in cell growth and increases in mature myeloid surface marker expression and apoptosis (Figures 6C and 6F ; Figures S6C-S6E) . Notably, the combination of SP600125 with either FOXO3 depletion or myr-Akt expression led to a significant decrease in cell growth and increases in apoptosis and mature myeloid surface marker expression compared to FOXO3 shRNA, myr-Akt expression, or SP600125 treatment alone (Figures 6B, 6C, 6E and 6F; Figures S6D-S6F) . Furthermore, SP600125 combined with myr-Akt resulted in morphological changes associated with myeloid differentiation ( Figure S6F ). Together, these data suggest that FOXO3 inhibition or AKT activation in AML results in JNK/c-JUN pathway activation mitigating the antileukemic properties of FOXO3 inhibition or AKT activation. Figure 5F ) with AML, we observed increased pc-Jun Ser63 in 75% of mice that died of AML despite efficient deletion of FoxO1/3/4 ( Figure 7A and Figures S5C-S5F) . We also evaluated the phosphorylation status of BM cells derived from control and myr-Akt-expressing leukemic mice from Figure S5H . Leukemic BM from four mice that succumbed to AML expressing MLL-AF9 and myr-Akt displayed elevated pc-Jun Ser63 compared to control leukemic BM ( Figure 7B ). Furthermore, all four myr-Aktexpressing AMLs displayed increases in pFoxO3 Ser256 , confirming that myr-Akt was inhibiting FoxO3 in these tumors ( Figure 7B ). To get a broader understanding of the relationship between FOXO inhibition and JNK/c-JUN activation in human AML, the expression of c-JUN was determined in the gene expression array dataset generated from 436 primary AML patient samples. c-JUN expression inversely correlated with FOXO activity and FOXO1 and FOXO3 expression (p < 0.0001; Figure 7C ). Collectively, these data demonstrate that inhibition of the AKT/FOXO signaling pathway preserves the immature phenotype and the leukemia-initiating properties of various AML subtypes. These data also suggest that activation of the JNK/c-JUN pathway represents a common mechanism by which AML tolerates the deregulation of FOXO/AKT signaling and offers a therapeutic opportunity of targeting deregulated JNK/c-JUN signaling in FOXO/AKT-deregulated AML.
DISCUSSION
In many human cancers, the serine/threonine kinase AKT promotes tumorigenesis by phosphorylating and inactivating targets that antagonize malignant growth, such as the FOXO family of transcription factors. We have identified an unexpected, yet crucial role of the FOXO signaling arm of the AKT pathway in the maintenance of the differentiation blockade in AML. We observed that Akt is repressed and FoxO1/3/4 are active in the MLL-AF9 AML cell fraction most highly enriched for LIC activity. Further, enforced activation of Akt or deletion of its canonical downstream targets, FoxO1, FoxO3, and FoxO4 (FoxO1/3/4-thought to be tumor suppressors), decrease leukemic growth and maintenance in vitro by promoting myeloid maturation and apoptosis. Ablation of FoxO1/3/4 in vivo reduced disease burden, diminished LIC function, and extended the life span of animals transplanted with MLL-AF9-positive AML. We confirmed the clinical relevance of our findings by demonstrating that FOXOs are active in primary samples derived from AML patients. We have also identified a mechanism of resistance to inhibiting FOXOs. Leukemias that persisted despite FoxO1/3/4 deletion or constitutive Akt activation exhibited c-Jun activation. Pharmacological inhibition of JNK augmented the myeloid maturation and apoptotic effects of Akt activation or FOXO inhibition. These data were supported by patient data where we noted that AML samples with reduced FOXO activity had increased expression of c-JUN. Taken together, the data suggest an inverse correlation of FOXO and JNK/c-JUN activation in AML, and that whereas FOXO depletion can induce a therapeutic differentiation of AML cells, increased JNK/c-JUN activity can render cells insensitive to FOXO loss. A combination of reduced FOXO and JNK/c-JUN activation may provide a particularly potent approach to AML.
The previously unrecognized relationship whereby blocking FOXO activity via direct inhibition or Akt activation activates JNK/c-JUN signaling is quite distinctive from prior reports that AKT inhibits JNK by inhibiting the JNK-activating kinase ASK1 (Kim et al., 2001) . Also, others noted that JNK can regulate FOXOs, particularly FOXO4, but we are unaware of prior evidence that FOXOs can inhibit JNK signaling (Essers et al., 2004; Wang et al., 2005) . Our data suggest that this relationship of AKT/ FOXOs to JNK/c-JUN is associated with AML surviving the activation of Akt and/or inhibition of FOXOs. These findings provide a rationale for considering JNK inhibition in antileukemic therapy.
It is not clear why we observed divergence between the results of Akt activation and FOXO inhibition on leukemia outcomes in vivo. However, it may be that some growth-promoting activities of Akt (such as activation of mTorc1 or inactivation of Gsk-3b) may provide countervailing signals in vivo that abrogate the effects of FoxO inhibition (Lee et al., 2010; Wang et al., 2008; Yilmaz et al., 2006) .
The genetic and molecular heterogeneity of AML has made the development of universal targeted therapies cumbersome and relatively unsuccessful. The broad bifurcation we have observed of AMLs based on their AKT, FOXO, and c-JUN signaling coupled with the impact that altering these pathways has on leukemia-initiating cells suggests a possible therapeutic opportunity for the development of more widely acting antileukemic agents.
EXPERIMENTAL PROCEDURES Plasmid and Mouse Generation
The MSCV-MLL-AF9 construct was a kind gift of Dr. S.A. Armstrong (Children's Hospital of Boston-CHOB). The MSCV-IRES-GFP-myr-Akt construct was kindly provided by Dr. K. Gritsman (Dana-Farber Cancer Institute) and Dr. Michael G. Kharas (CHOB) . The MSCV-puro-CreER plasmid was kindly donated by Dr. D. Kalaitzidis (CHOB). The expression plasmid carrying the LSL-hCD34 was kindly donated by Dr. M. Milsom (Heidelberg University). The FoxO1/3/4 floxed ;Mx1-Cre + mice were generated previously (Paik et al., 2007; Tothova et al., 2007) .
AML Patient Samples
BM aspirates from patients with AML were collected under a protocol approved by the institutional review board (IRB) of Massachusetts General Hospital. Ficoll density gradient was then used to recover viable mononuclear cells from BM aspirates. MNBCs recovered from leukemic mice were then transplanted into secondary sublethally irradiated recipients. Fourteen days after transplant, secondary recipients were administered intraperitoneally three doses of saline or 12.5 mg/kg pI-pC (Amersham) every 2 days. Mice were then monitored for external (i.e., moribund) and internal (white blood cell counts) signs of leukemia.
MLL-AF9 Retroviral Bone Marrow Transplantation Assay
Flow Cytometry and Antibodies
MNBCs were stained with a lineage cocktail comprised of antibodies targeting CD3, CD4, CD8, CD19, B220, Gr-1, Ter119, and IL-7Ra. MNBCs were also stained with antibodies targeting cKit, Sca-1, FcgRII/III, and CD34. L-GMP and GMP populations were analyzed and sorted with a FACSAria instrument (Becton Dickinson). For phosphoflow experiments, lineage low cells were sorted and stained with cKit and CD34 antibodies in combination with phospho-AKT Ser473 , phospho-AKT
Thr308
, or phospho-S6 Ser235/236 antibodies and then analyzed on a FACSAria. Primary AML patient BM cells were stained with human CD34 and lineage cocktail. Antibody information including company, clone, and dilution factor are listed in Table S2 .
Cell Death Assays
Cells were stained with Annexin V and 7-AAD according to the manufacturer instructions (BD Biosciences) to assess levels of apoptosis. Where indicated, cell death was also evaluated with Trypan Blue staining (Cellgro).
Phagocytosis Assay
Phagocytosis was assessed using a pHrodo BioParticles Conjugates for Phagocytosis Kit (Invitrogen). Assays were performed according to the manufacturer's instructions.
Indirect Immunofluorescence
Cytospins of purified L-GMPs and GMPs were fixed with PFA and permeabilized with methanol. Processed cells were then subjected to staining with FOXO3 (75D8) antibodies. Cells were then incubated with an anti-rabbit FITC-conjugated secondary antibody (1:2000; Sigma). Cells were also stained with DAPI to visualize nuclei and visualized under 1003 magnification using a Nikon fluorescence microscope.
Cell Fractionation
Cells were resuspended in hypotonic buffer containing a mild detergent to rupture cellular membrane. Recovered nuclei lysed in a hypertonic solution and cytoplasmic fractions were subjected to western blotting with the corresponding antibodies.
Cell Morphology Staining
Cells from respective conditions were stained first with May-Grü nwald dye and then Giemsa stain (Sigma). Alternatively, cells were permeabilized and stained in 100% Wright-Giemsa stain and then stained with 20% Wright-Giemsa/80%.
Colony Assays
Murine myeloid colony assays were plated in M3434 cytokine-enriched methylcellulose according to manufacturer's instructions (Stem Cell Technologies). Human myeloid colony assays were plated in H4034 cytokine-enriched methylcellulose according to manufacturer's instructions (Stem Cell Technologies). For CAFC assays, murine leukemia cells were cocultured on OP9 stroma cells for 7-14 days. 
Statistical Analyses
